To the best of our knowledge, this is the first report of an investigation of regorafenib-induced liver injury in patients with metastatic colorectal cancer using solicited postmarketing data from real-world clinical practice. Overall, the clinical features were comparable to those in the clinical trials, including idiosyncratic occurrence and hepatocellular type. Early recognition and timely drug withdrawal are crucial for preventing severe outcomes. Background: Regorafenib (Stivarga) is an oral multikinase inhibitor currently approved for patients with metastatic colorectal cancer or gastrointestinal stromal tumor. Although hepatotoxicity has been a known product profile feature of regorafenib since its initial approval, its clinical features are limited to those found in the clinical trials. Patients and Methods: The present study was conducted in 2 analysis sets: a safety analysis set for metastatic colorectal cancer from solicited postmarketing surveillance (PMS) in Japan (n ¼ 1227) and an analysis set for serious hepatic adverse drug reactions (n ¼ 210) from all patients registered for regorafenib use. Results: The features of liver injury compatible with current product labeling included the second cycle as the most frequently observed time to onset, hepatocellular type as the typical pattern of liver injury, idiosyncratic occurrence as the possible mechanism, and rare fatal outcomes (0.33%; 4 of 1227). In addition to the known features, the present study found unpredictability in the outcome of hepatic events using the onset values of liver chemistry tests and delayed improvement of hepatic parameters after drug withdrawal. Owing to multiple confounding factors in patients with advanced cancer, difficulty remains in the interpretation of exploration for background factors and evaluation using Hy's law in oncology products. Conclusion: Regorafenib-induced liver injury can be considered idiosyncratic and typically of hepatocellular type, with fatal outcomes rare. Early recognition and timely drug withdrawal are the most important strategies to prevent progression to severe outcomes. At occurrence, careful observation until improvement and monitoring for fulminant hepatic failure are also essential.
Introduction
Regorafenib (Stivarga) is an oral multikinase inhibitor that blocks the activity of a number of protein kinases associated with angiogenesis (vascular endothelial growth factor receptors 1 to 3 and TIE2), oncogenesis (KIT, RET, RAF1, BRAF, and BRAF V600E), and the tumor microenvironment (platelet-derived growth factor receptor and fibroblast growth factor receptor). 1 Regorafenib was approved for unresectable metastatic colorectal cancer (mCRC) in 1 Japan in March 2013 based on the results from the pivotal phase III CORRECT (patients with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy) study (ClinicalTrials.gov identifier, NCT01103323), which compared the efficacy and safety of regorafenib to placebo in patients with mCRC that progressed during standard therapy. 2 The additional indication for gastrointestinal stromal tumor (GIST) with progression after cancer chemotherapy was approved in August 2013. A post hoc analysis of the CORRECT study showed that regorafenib appeared to have comparable efficacy in Japanese and non-Japanese subpopulations, with a manageable safety profile. 3 In the product label, hepatotoxicity was included in a boxed label warning at its initial approval, based on the results of the COR-RECT study. The boxed warning describes the occurrence of severe and sometimes fatal hepatotoxicity, the need for monitoring of hepatic function before and during treatment, and the need for dose interruption, reduction or discontinuation of regorafenib. 4 However, the information on which it was based has been limited to that obtained from clinical trials and several case reports. The mechanism of hepatotoxicity is associated with chemically reactive metabolites 5 and several signal transduction pathways that modulate cell death or survival 6 or the mitochondrial involvement. 7 Although many tyrosine kinase inhibitors (TKIs) have labels that require monitoring of liver function during their clinical use according to the Food and Drug Administration, the mechanisms of hepatotoxicity in TKIs have not been fully elucidated owing to their pharmacologic diversity. 8 A Japanese postmarketing surveillance (PMS) was conducted under the instruction of the Japanese Health Authority to assess the safety and efficacy of regorafenib for the treatment of mCRC and GIST (ClinicalTrials.gov identifier, NCT01843400) in real-world clinical practice.
The objective of the present study was to investigate additional clinically useful information on the hepatic safety of regorafenib using Japanese real-world data for further reinforcement of its proper use.
Patients and Methods

Analysis Sets
The present study was conducted using 2 analysis sets: a safety analysis set for mCRC PMS (n ¼ 1227; analysis set A) and an analysis set for serious hepatic adverse drug reactions (ADRs; n ¼ 210; analysis set B; Figure 1 ).
In the mCRC PMS, case report forms (CRFs) were completed by the investigators and collected by Bayer Yakuhin, Ltd. The patient baseline demographic data, laboratory data, safety, and efficacy were collected using the CRFs. The safety analysis set from the mCRC PMS (n ¼ 1227; analysis set A) was used to elucidate the patient baseline demographic data, investigation of liver chemistry abnormalities, and exploration of background factors affecting the occurrence of serious hepatic ADRs.
The analysis set for serious hepatic ADRs (n ¼ 210; analysis set B) included information from detailed investigation of ADRs using a special questionnaire for all reported cases, including both the PMS and spontaneous reports (n ¼ 395). To secure patient safety, all the patients were registered at Bayer Yakuhin, Ltd. by facsimile before their first administration of regorafenib (8380 in total as of July 8, 2016 ). The information on any adverse events (AEs) was collected by Bayer Yakuhin, Ltd. from prescribing physicians on a reporting basis in accordance with the Japanese pharmaceutical Regorafenib-induced Liver Injury From Japanese Postmarketing regulations. The reported terms were encoded using the Medical Dictionary for Regulatory Activities Preferred Terms (MedDRA PT).
Investigation of Liver Chemistry Abnormalities
From the safety analysis set for mCRC PMS (n ¼ 1227; analysis A), liver chemistry abnormalities were analyzed, irrespective of whether they had been reported as an AE. "Possible Hy's law cases" were extracted in accordance with the guidance of the Food and Drug Administration regarding drug-induced liver injury (DILI), any elevated aminotransferase of > 3 Â upper limit of normal (ULN), alkaline phosphatase (ALP) < 2 Â ULN, and association with an increase in bilirubin ! 2 Â ULN.
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Clinical Characteristics of Patients With Serious Hepatic ADRs
Detailed information on the serious hepatic ADRs (ie, hepatic AEs assessed as serious and associated with regorafenib use by either the reporting physicians or Bayer Yakuhin, Ltd.) was collected using a special questionnaire, including the clinical course, laboratory data, therapy for liver injury, and any other diagnostic parameters. The criteria for assessment as serious were in accordance with the International Conference on Harmonization E2D guidelines. 11 
Medical Review of Fatal Cases and Possible Hy's Law Cases
Fatal cases were defined as the outcome of hepatic ADRs as fatal as assessed by the reporting physicians. Clinical information on the fatal cases and possible Hy's law cases were reviewed by Dr Hajime Takikawa (expert hepatologist). Input from the Stivarga Proper Use Advisory Committee, consisting of a board of experts, was also obtained for a clinical perspective of patients with underlying mCRC or GIST.
Statistical Analysis
A comparison between the onset of abnormal levels and the peak in those levels in liver chemistry tests was performed using the Wilcoxon t test, with a level of significance of 5%. To explore the background factors affecting the occurrence of serious hepatic ADRs, univariate and multivariate analyses were performed in a stepwise manner using the Cox proportional hazard model with a significance level of 5%. The response variable was the presence or absence of serious hepatic ADRs. On univariate analysis, all baseline items on the CRFs were used as explanatory variables. The correlation among all explanatory variables was evaluated using the Spearman rank correlation coefficient. From the multivariate analysis, 11 explanatory variables were selected among all baseline items on the CRFs. Of the 11, 9 were selected from a medical point of view (gender [ analyses were conducted: a univariate analysis using the median, 1.2 mg/dL, and 2.0 mg/dL as cutoff values for the baseline T-Bil and a logistic regression analysis to explore any baseline factors affecting the start dose (< 160 vs. 160 mg). The statistical analyses were performed using SAS software, version 9.2.
Results
Patient Demographics in mCRC PMS
The patient baseline demographics are listed in Table 1 for the overall population of the safety analysis set for mCRC PMS (n ¼ 1227; analysis set A) and the patients with serious hepatic ADRs in the mCRC PMS (n ¼ 140, within analysis set A).
Investigation of Liver Chemistry Abnormalities
The results of the investigation of liver chemistry abnormalities in the safety analysis set for mCRC PMS are listed in Table 2 . Of the 1227 patients in safety analysis set, 16 were possible Hy's law cases (1.3%).
Clinical Characteristics of Patients With Serious Hepatic ADRs
The special questionnaires for serious hepatic ADRs were collected from 210 (analysis set B) of the 395 patients with a report of serious hepatic ADRs with the cooperation of their reporting physician ( Figure 1 ).
Onset and Peak of Abnormal Liver Chemistry Test Results.
Among the 210 patients with completed questionnaires, the onset and peak values were compared between those with fatal and nonfatal outcomes ( Figure 2 ). The peak values of AST, ALT, and T-Bil for the patients with fatal outcomes were significantly greater than those for the patients with nonfatal outcomes. In contrast, the values at onset in those with fatal outcomes, except for T-Bil, were not significantly greater than in those with nonfatal outcomes.
Interval to Onset and Changes in Liver Chemistry Tests After
Starting or Withdrawing Regorafenib. The median interval to the onset of elevated AST, ALT, and T-Bil levels was 35.0 days (5th to 95th percentile, 7-97 days), 35.0 days (5th to 95th percentile, 7-96 days), and 38.5 days (5th to 95th percentile, 6-116 days), respectively. These were consistent with the beginning of cycle 2 of regorafenib treatment. Worsening of the AST, ALT, and T-Bil liver chemistry test values was observed even after withdrawal of regorafenib in 90 (42.9%), 92 (43.8%), and 102 (48.6%) of 210 patients, respectively.
Clinical Symptoms, Therapy for Livery Injury, and Liver Biopsy Findings. Of the 210 patients, 125 (59.5%) were reported as asymptomatic at onset. In the 81 symptomatic patients, the major symptoms were fatigue in 54, jaundice in 30, appetite decreased in 29, and fever in 14, followed by dark urine, epigastric or hypochondriac pain, skin symptoms, and nausea or vomiting in 9, 7, 4, and 3 patients, respectively.
Of the 210 patients, 118 received therapy for liver injury (56.2%). The therapy for liver injury included liver-supporting agents (glycyrrhizic acid, ursodeoxycholic acid in 112 patients), corticosteroids in 46, other medications in 18, and artificial liver
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Medical Review of Fatal Cases and Possible Hy's Law Cases
The results of medical review are shown in Figure 3 . Overall, a fatal outcome resulting from serious hepatic ADRs was reported for 27 of an estimated 8380 patients with exposure to regorafenib. Of these 27 patients, 12 had presented with a hepatocellular pattern of liver chemistry abnormalities and had also met the criteria for fulminant hepatic failure. Of these 12 patients, 5 met the criteria for acute fulminant hepatitis, in whom the consciousness disturbance occurred within 10 days from onset, and 7 patients had subacute fulminant hepatitis, which developed > 10 days from onset. In the safety analysis set for mCRC PMS (n ¼ 1227; analysis set A), 7 patients were reported to have died of hepatic ADRs, and 4 presented with a hepatocellular pattern of liver injury. Patients presenting with patterns other than hepatocellular liver injury had confounding factors such as pre-existing possible cholestasis due to multiple liver metastases, progression of underlying mCRC or GIST, or other events that secondarily caused liver injury.
A medical review of the 16 possible Hy's law cases revealed that 9 were considered "true" regorafenib-induced liver injury presenting with a hepatocellular pattern. Of these 9 patients with a hepatocellular pattern, 2 died and 7 improved or recovered. The remaining 7 patients had other events that secondarily caused liver injury.
Background Factors Affecting the Occurrence of Serious Hepatic ADRs
The multivariate analysis in the safety analysis set for mCRC PMS revealed that the starting dose (< 160 mg vs. 160 mg) and baseline T-Bil (! 1.2 vs. < 1.2 mg/dL) affected the occurrence of serious hepatic ADRs, with a significance level of 5% (Figure 4) . The hazard ratio (HR) was 0.605 (95% confidence interval [CI], 0.385-0.950) for a start dose of < 160 mg and 2.071 (95% CI, 1.197-3.585) for baseline T-Bil ! 1.2 mg/dL. The data availability of the multivariate analysis for 11 selected explanatory variables was 68.1% (836 of 1227). No strong correlation (Spearman rank correlation coefficient, < À0.5 or > 0.5) was found between any of the explanatory variables, except for those with correlation owing to their definition (eg, male gender and smoking history, body weight, and body mass index).
The univariate analyses of the median (0.6 mg/dL), 1.2 mg/dL, and 2.0 mg/dL as cutoff values for baseline T-Bil revealed significant differences, except for 2.0 mg/dL (HR, 1.492; 95% CI, 1.022-2.180 for the median; and HR, 2.236; 95% CI, 1.353-3.694 for ! 1.2 mg/dL) The HR for ! 2.0 mg/dL was 1.168 (95% CI, 0.289-4.726). These 15 patients with a baseline T-Bil of ! 2.0 mg/dL were reviewed. In 13 of the 15 patients, serious hepatic events were not reported because the reporting physicians had considered them to result from the natural course of underlying mCRC progression. The logistic regression analysis exploring any affect for a starting dose < 160 mg revealed that age ! 65 years, body weight stratified by gender less than the median, and the presence of lymph node metastasis resulted in significantly greater odds ratios (Supplemental Table 1 ; available in the online version). The data availability for the logistic regression analysis for the start dose was 63.7% (781 of 1227).
Discussion
The importance of the present study is that we not only proved that some features of hepatotoxicity resulting from regorafenib in real-world clinical practice are comparable with the known profile from clinical trials, but also added several new findings. Investigators have recently been focused on how well real-world evidence reflects actual patient populations with varied backgrounds and how well it supplements information useful for daily medical practice. Active collection of medically confirmed safety information from prescribing physicians under the Japanese pharmaceutical regulations allowed for a qualified, largescale postmarketing analysis, in contrast to overseas postmarketing situations. 
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The features comparable to the known profile were as follows: the second cycle as the most frequently observed time of onset, the hepatocellular pattern of liver injury as typical, idiosyncratic occurrence as a possible mechanism, and rare fatal outcomes. The mean interval to onset (range, 35.0-38.5 days) was comparable to the observation in the clinical trials and consistent with the current recommendation to monitor the hepatic parameters weekly 12 
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comprehensive medical review of fatal cases and possible Hy's law cases revealed that the major pattern of the liver chemistry test results was the hepatocellular type and the patients presenting with other patterns had strong confounding factors. This finding was also consistent with the liver biopsy results, which showed hepatocyte necrosis with lymphocyte infiltration. 13 The incidence of a fatal outcome from "true" regorafenib-induced liver injury was 0.33% (4 of 1227), which was comparable to the 0.3% in the 1200 Stivarga-treated patients 13 and 1.5% of Japanese patients 4 across all clinical trials listed on the current product label. This suggests that risk mitigation in Japanese postmarketing setting was considered effective by the early recognition of hepatic events, treatment withdrawal of regorafenib, and appropriate therapeutic interventions. In principle, therapeutic interventions for DILI remain limited to the cessation of the suspected drugs, supportive care, and monitoring for fulminant hepatic failure. 14 Once fulminant hepatic failure has developed, patients should be treated in an intensive care setting, and artificial liver support should be considered, such as plasma exchange and continuous hemodiafiltration. 15, 16 In the present study, artificial liver support was provided for only 8% of patients, suggesting difficulty in determining the appropriateness of its use from the perspective of the benefit/risk evaluation in patients with advanced cancer.
The new findings adding to the understanding of features of regorafenib-induced liver injury include the unpredictability of the outcome of hepatic events according to the onset of abnormal values in the liver chemistry tests and delayed improvement of the hepatic parameters after regorafenib withdrawal. The values of AST and ALT at the onset in the patients with fatal outcomes were not significantly greater than those in the patients with nonfatal outcomes. Thus, they were not predictive factors for the prognosis of hepatic events. In contrast, the significantly greater T-Bil levels at onset possibly originated from patients with pre-existing cholestasis due to multiple liver metastases. Also, 59.5% of the patients in the analysis set of serious hepatic events were asymptomatic at onset and the liver failure was captured only by monitoring the liver chemistry test results. Delayed improvement of the hepatic parameters, shown by the worsening liver parameters even after regorafenib withdrawal in 42.9% to 48.6% of the analysis set of serious hepatic events, might be associated with the pharmacokinetics of regorafenib and its active metabolites. According to the data from a Japanese phase I study, the genomic mean terminal half-life of regorafenib, regorafenib N-oxide metabolite (M2), and regorafenib N-oxide/N-desmethyl metabolite (M5) after a single dose was 27.4, 24.8, and 60.8 hours, respectively. 17 Taken together, the most important strategies for preventing regorafenib-induced liver injury from progressing to a severe outcome are as follows: prescribing physicians should carefully observe the hepatic parameters and clinical manifestations of the patients, regardless of the onset liver chemistry test values, regardless of the presence or absence of clinical symptoms at onset, and after regorafenib withdrawal until improvement has occurred. Physicians also should monitor for fulminant hepatic failure and immediately start therapy in an intensive care setting for the consequent events of severe liver injury, such as infection, renal failure, and disseminated intravascular coagulation.
The present study also found 1 issue, in that the application and interpretation of the conventional Hy's law poses challenges with oncology products. For drug-induced hepatotoxicity, regulatory authorities have released guidelines based on "Hy's law" to predict the postapproval risk of serious hepatotoxicity to allow for its earlier detection and risk mitigation. 10, 18 In the present study, the postmarketing evaluation of possible Hy's law cases (1.3%; 16 of 1227) was comparable to that in the overall population (0.8%; 4 of 500) and in the Japanese subpopulation (1.7%; 1 of 59) in the COR-RECT study. 12 However, the comprehensive medical review of the 23 The evaluation of hepatotoxicity in patients with HCC will be more difficult and requires further discussion. Another remaining issue is exploration of the background factors affecting the occurrence of serious hepatic ADRs. In general, susceptibility to DILI is influenced by the interplay among age, gender, concurrent drug therapy, environmental factors, underlying disease, and genetic preposition. 14 In the multivariate analysis of the present study, the baseline T-Bil level (! 1.2 vs. < 1.2 mg/dL) and starting dose (< 160 vs. 160 mg) were identified as background factors with significantly higher and lower HRs, respectively. The greater baseline T-Bil level might suggest that the potential cholestasis due to liver metastasis plays a possible role in causing serious hepatic events. However, in patients with a baseline T-Bil level of ! 2.0 mg/dL, the prescribing physicians considered the hepatic events to result from progression of the underlying malignancy rather than from the drug. However, the risk factors causing "pure" idiosyncratic regorafenib-induced liver injury without potential cholestasis remain unknown. The interpretation of a lower HR for a lower starting dose is also difficult, because the starting dose was affected by physicians' medical decisions considering the complicated clinical background of the patients with advanced cancer. Genetic predisposition was not investigated, because the present mCRC PMS was a noninterventional surveillance. Recent reports have demonstrated associations between the susceptibility of liver injury and older age with pazopanib, 24 genetic predispositions such as UG1T1A1*28 polymorphism with irinotecan, 25 and HLA-DQA1*02:01 with lapatinib. 26 Regarding the effect of ethnicity with regorafenib usage, the current product label reports that integrated analysis of clinical trials revealed a greater incidence of handfoot skin reactions, severe liver function test abnormalities, and hepatic dysfunction in Asian (in particular, Japanese) patients compared with Caucasians. 4 For other TKIs, no clear description regarding the effects of ethnicity has been provided on their product labels to date. The genetic aspect causing a greater incidence of regorafenib-induced liver injury in Japanese patients has not yet been fully elucidated. The predictive biomarkers of liver injury should be explored further.
Conclusion
Regorafenib-induced liver injury in the current indications (mCRC and GIST) can be considered idiosyncratic, typically of a hepatocellular pattern, and rarely fatal. Early recognition and timely drug withdrawal are the most important strategies for preventing regorafenib-induced liver injury from progressing to severe outcomes.
Clinical Practice Points
Although the hepatotoxicity of regorafenib has been a known product profile feature since its initial approval, the information on its clinical features has been limited to that from the clinical trials. Because the active collection of safety information is required under Japanese pharmaceutical regulations, qualified and largescale postmarketing data were available in real-world clinical practice. According to these data, the overall hepatic safety of regorafenib in Japanese postmarketing experience was comparable to that in the clinical trials. Although the evaluation of liver injury is difficult in advanced cancer patients owing to their multiple confounding factors, the present study using a comprehensive medical review revealed that regorafenib-induced liver injury can be considered idiosyncratic, typically of a hepatocellular pattern, and rarely fatal. For the proper use of regorafenib, careful observation of the hepatic parameters and clinical manifestations of the patients are required, especially during the first 2 cycles. Early recognition and timely drug withdrawal are the most important strategies for preventing regorafenib-induced liver injury from progressing to severe outcomes. Monitoring for fulminant hepatic failure and therapeutic intervention of its consequent events are also essential. 
